HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Primary cutaneous lymphoma — Clinical Guidelines

Overview

Primary cutaneous lymphomas (PCLs) are a heterogeneous group of lymphoproliferative disorders that originate in the skin without systemic involvement at diagnosis. They encompass various subtypes, including T-cell and B-cell lymphomas, each with distinct clinical and pathological features 2 12.

Diagnosis

Clinical Presentation: Solitary or multiple skin lesions, often with characteristic morphology (e.g., plaques, nodules, ulcerations) 3 8.

Histopathological Examination: Essential for diagnosis, including immunohistochemical staining to identify cell lineage (T-cell or B-cell) 2 3 7.

Clonality Assays: Recommended for confirming lymphomatous proliferation, particularly in borderline cases 7.

Imaging: Used to rule out systemic involvement, including CT scans and PET scans 2.

Laboratory Tests: Elevated lactate dehydrogenase (LDH) levels can indicate aggressive disease 6.

Dermoscopy/Trichoscopy: Non-invasive tools aiding in diagnosis, though standardized features are still evolving 4.

Management

First-Line Treatments:

- Topical Agents: Corticosteroids, nitrogen mustard, and retinoids for localized disease 2. - Systemic Therapy: For advanced or refractory cases, options include: - Immunotherapy: Interferon, IL-2 2. - Chemotherapy: CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) 2. - Targeted Therapy: JAK inhibitors (though concerns exist regarding potential risks like cutaneous lymphoma development 1).

Adjunctive Treatments:

- Radiation Therapy: Total or partial skin electron beam therapy for localized disease 17. - Phototherapy: Narrowband UVB for mycosis fungoides 17.

Special Populations

Pediatrics: Rare but requires prompt diagnosis and treatment; combination chemotherapy can be effective 16.

Elderly: Tailored treatment approaches considering comorbidities and tolerability; systemic involvement must be carefully monitored 2.

Comorbidities: Functional asplenia noted in Sezary syndrome necessitates careful management of infections 15.

Key Recommendations

Comprehensive Diagnostic Workup: Include histopathological examination, immunohistochemical staining, and imaging to rule out systemic involvement (Evidence: Strong 2 6).

Tailored Treatment Based on Subtype and Stage: Utilize topical agents for localized disease and systemic therapies like CHOP for advanced cases (Evidence: Moderate 2).

Monitor LDH Levels: Elevated LDH can indicate aggressive disease course and guide treatment intensity (Evidence: Moderate 6).

Consider Functional Comorbidities: In elderly patients or those with conditions like Sezary syndrome, manage potential complications such as functional asplenia (Evidence: Expert opinion 15).

Use of Novel Therapies with Caution: Evaluate risks and benefits of targeted therapies like JAK inhibitors given potential lymphoma development concerns (Evidence: Weak 1).

References

1 Lu L, Feng J, He H, Peng Y, Zhang S, Yang L et al.. Cutaneous Lymphoma Associated with JAK Inhibitors: A Pharmacovigilance Analysis of the FAERS Database and Literature Review. Acta dermato-venereologica 2026. link 2 Hamada T, Sugaya M, Sakaida T, Hirai Y, Boki H, Shimauchi T et al.. Japanese Dermatological Association Guidelines: Outlines of Japanese Guidelines for the Management of Primary Cutaneous Lymphomas 2025. The Journal of dermatology 2025. link 3 Paudel U, Parajuli S. Clinical and Pathological Features of Primary Cutaneous Lymphomas in Nepal: A retrospective cohort study from a dermatology referral centre. Kathmandu University medical journal (KUMJ) 2024. link 4 Sławińska M, Sokołowska-Wojdyło M, Olszewska B, Nowicki RJ, Sobjanek M, Zalaudek I. Dermoscopic and trichoscopic features of primary cutaneous lymphomas - systematic review. Journal of the European Academy of Dermatology and Venereology : JEADV 2021. link 5 Torre-Castro J, Estrach T, Peñate Y, Acebo E, Fernández de Misa R, Blanes M et al.. Primary cutaneous lymphomas in children: A prospective study from the Spanish Academy of Dermatology and Venereology (AEDV) Primary Cutaneous Lymphoma Registry. Pediatric dermatology 2021. link 6 Livesey A, Garty F, Shipman AR, Shipman KE. Lactate dehydrogenase in dermatology practice. Clinical and experimental dermatology 2020. link 7 Comfere N, Sundram U, Hurley MY, Swick B. Views of dermatopathologists about clonality assays in the diagnosis of cutaneous T-cell and B-cell lymphoproliferative disorders. Journal of cutaneous pathology 2018. link 8 Spałkowska M, Brzewski P, Walter S, Jaworek AK, Sułowicz J, Andres M et al.. Primary cutaneous lymphomas: the analysis of cases treated in the Department of Dermatology University Hospital in Krakow. Przeglad lekarski 2016. link 9 Wang L, Wang G, Gao T. Acneiform primary cutaneous CD4-positive small/medium pleomorphic T-cell lymphoma with prominent necrosis. Journal of cutaneous pathology 2015. link 10 Payzin B, Ogretmen Z, Cidem Yildirim A, Ozturk Durur S, Sentekin S. Primary cutaneous lymphomas: single center experience of dermatology and hematology clinics. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 2014. link 11 Assaf C, Gellrich S, Steinhoff M, Nashan D, Weisse F, Dippel E et al.. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2007. link 12 Burg G, Kempf W, Cozzio A, Döbbeling U, Feit J, Golling P et al.. Cutaneous malignant lymphomas: update 2006. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2006. link 13 Burger GT, Van Ginneken AM, Hollema H. Computer-based diagnostic support systems in histopathology: what should they do?. Studies in health technology and informatics 2001. link 14 Okano M, Nakajima C, Uehara H, Tsujimoto T. Bullous lymphoma of the skin. The British journal of dermatology 1994. link 15 Balachandran S, Kumar R, Kuo TT. Functional asplenia in Sezary syndrome. Clinical nuclear medicine 1980. link 16 Kukreja S, Zarkowsky H. Cutaneous lymphoma in an infant: case report. Medical and pediatric oncology 1979. link 17 Goldschmidt H, Lukacs S, Schoefinius HH. Teleroentgen therapy for mycosis fungoides. The Journal of dermatologic surgery and oncology 1978. link

Primary cutaneous lymphoma